Compare Pfizer Inc (PFE) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Snap Inc — how do they compare? Pfizer Inc trades at $28.16 (market cap $158.56B), while Snap Inc trades at $6.25 (market cap $9.83B). The key difference: Pfizer Inc is far larger — about 16.1× Snap Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Snap Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Snap Inc for 68 Days on average.
| PFE | SNAP | |
|---|---|---|
Market Cap | $158.56B | $9.83B |
Volume | 44,138,282 | 28,532,342 |
Sector | Health | Media |
52-Week High | $29.02 | $9.09 |
52-Week Low | $23.67 | $3.93 |
Typical Hold Time | 158 Days | 68 Days |
Enterprise Value | $210.06B | $11.39B |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Snap Inc. (SNAP) trades at $6.235, up 7.31% on the day, with a bullish technical signal from moving averages but a neutral oscillator stance. Revenue growth is steady, reaching $5.93B in 2025, though the company remains unprofitable with a net income margin of -4.9%. Recent news highlights AI and AR developments, including partnerships with NVIDIA and Salesforce for its SPECS glasses, driving positive sentiment despite regulatory pressures.
The stock presents a speculative opportunity with analyst consensus pointing to a $7.78 price target, but risks include persistent losses, high debt, and intense competition. Upside hinges on monetizing new AI/AR initiatives, while downside protection is limited by weak profitability and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
